



Disclaimer

This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but that may not prove to be accurate. By their nature, forward-looking statements involve risk and uncertainty. Consequently, the company cannot guarantee their accuracy and their completeness, and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of.

For additional information concerning important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the Autorité des Marchés Financiers.

Any forward-looking statement speaks only as of the date on which it is made, and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Cette présentation contient des "déclarations prospectives" au sens de la loi « Private Securities Litigation Reform Act » de 1995. Les déclarations prospectives sont fondées sur des attentes et des hypothèses que nous estimons raisonnables au moment où elles sont formulées, mais qui peuvent s'avérer inexactes. De par leur nature, les déclarations prospectives impliquent des risques et des incertitudes. Par conséquent, l'entreprise ne peut garantir leur exactitude et leur exhaustivité, et les résultats réels peuvent différer matériellement de ceux anticipés par l'entreprise en raison d'un certain nombre d'incertitudes, dont la plupart ne sont pas connues de l'entreprise.

Pour plus d'informations sur les facteurs importants susceptibles d'entraîner une différence significative entre les résultats réels de la société et les attentes et hypothèses sous-jacentes, veuillez vous référer aux rapports déposés par la société auprès de l'Autorité des Marchés Financiers.

Toute déclaration prospective n'est valable qu'à la date à laquelle elle est faite, et nous n'assumons aucune obligation de mettre à jour ou de réviser une déclaration prospective, que ce soit à la suite de nouvelles informations, d'événements futurs ou pour toute autre raison, sauf si la loi l'exige.



The Q1 2023 Big picture

Revenue
Q1 2023

€145.9m

+12.9%
reported


+12.2%
LFL

Revenue

- Continued sales momentum in the first quarter
- All divisions are contributing positively to the growth
- Accelerating growth for Cegedim Santé




1Q 2023 Revenue up 12.2% L.f.I





1Q 2023 Revenue growth by division






Software & Services

55.1%
Of 1Q Group revenue

€80.4m
Revenue

+12.9%
+€9.2m



In million €	Revenue		Change 2023 / 2022		
	1Q 2022	1Q 2023	€ m	% Reported	% L.f.l.
Total Software & services	71.2	80.4	9.2	+12.9 %	+12.0 %
<i>Cegedim Santé</i>	14.7	20.6	5.9	40.1%	33.2%
<i>Insurance, HR, Pharmacies, and other services</i>	44.5	47.3	2.8	6.2%	6.0%
<i>International businesses</i>	12.0	12.5	0.5	4.4%	8.1%

Comments

- Cegedim Santé picked up its pace of growth : +33% Like for like, among with €2.8m are linked to « Ségur de la Santé ».
- Other French activities grew sales by 6.2%, buoyed by HR activities and other services
- International businesses returned to growth, particularly in the doctor and insurance segments in the UK




Flow

17.0%
Of 1Q Group revenue

€24.8m
Revenue

+9.7%
+€2.2m



In million €	Revenue		Change 2023 / 2022		
	1Q 2022	1Q 2023	€ m	% Reported	% L.f.l.
Total Flow	22.6	24.8	2.2	9.7%	9.9%
e-business	13.7	15.0	1.3	9.5%	9.9%
Third-party payment	8.9	9.8	0.9	9.9%	9.9%

Comments

- The process digitalization and digital data flow business grew by 9.5%. Both French and international activities contributed to the growth.
- Third-party payer systems in France had an excellent first quarter, up nearly 10%, owing to strong invoice volumes in pharmacies and rising volumes in the hospital segment.




Data & Marketing

16.9%
Of 1Q Group revenue

€24.6m
Revenue

+9.5%
+€2.1m



	Revenue		Change 2023 / 2022		
	1Q 2022	1Q 2023	€ m	% Reported	% L.f.l.
<i>In million €</i>					
Total Data & Marketing	22.5	24.6	2.1	9.5%	8.3%
Data	12.3	13.1	0.8	6.3%	4.1%
Marketing	10.2	11.5	1.4	13.4%	13.4%

Comments

- Most of the growth in Data activities came from French sales. The positive scope effect of +2.2% was attributable to the first-time consolidation of Clinityx.
- Advertising in pharmacies had a promising start to the year, growing by double digits.




BPO

9.9 %
Of 1Q Group revenue

14.4 M€
Revenue

+17.8%
+€2.2m



In million €	Revenue		Change 2023 / 2022		
	1Q 2022	1Q 2023	€ m	% Reported	% L.f.l.
Total BPO	12.3	14.4	2.2	17.8%	17.8%
Insurance BPO	7.5	8.8	1.2	16.3%	16.3%
HR BPO	4.7	5.7	1.0	20.2%	20.2%

Comments

- BPO operations continued to post double-digit growth over the first quarter, driven equally by services aimed at health and personal protection insurance companies, and by those designed for clients' HR departments.




Outlook

Outlook 2023



2023 Revenue

+ 10%
Like for Like



Recurring operating income



Disclosure: Based on currently available information.
The Group does not expect to make any significant acquisitions in 2023. And lastly, the Group does not provide earnings estimates or forecasts.



2023 – Financial agenda

June 16

Shareholders'
meeting

2023

July 27

After the market closes

Revenue
1st semester

2023

September 20

After the market closes

Earnings
first semester


2023

October 26

After the market closes

Revenue
3rd quarter

2023



Thank you for your attention

For any additional information
Investor.relations@cegedim.com

www.cegedim.com/finance

Download our mobile app Cegedim IR in iOS and Android and follow us on



Public company with share capital of 13,336,506.43€ | 137 rue d'Aguesseau 92100 Boulogne-Billancourt